CompletedPHASE1, PHASE2NCT00637221

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Neuropharm
Principal Investigator
Mike Snape, PhD
Neuropharm Ltd
Intervention
NPL-2009(drug)
Enrollment
12 enrolled
Eligibility
18-45 years · All sexes
Timeline
20082008

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00637221 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials